Israel’s Purple Biotech (see here previously) has partnered with the Icahn School of Medicine at Mount Sinai New York, to develop CAPTN-3, a platform of activated antibodies. The aim is to enhance tumor-specific immunity against various cancer types. https://purple-biotech.com/press-viewer/?i=142208

Israel’s Purple Biotech has two promising treatments for solid tumors in clinical (human) trials. CM24 has completed Phase 1 and is in Phase 2 for Pancreatic cancer. NT219 is in Phase 1/2 in the USA. Purple is also partnering Mor, … Continue reading →